Transition Metal Complexes for Anticancer Therapy and Cisplatin Resistance
This community designs and evaluates metal-based compounds—primarily platinum, ruthenium, and copper complexes—to treat cancer and to address the specific problem of resistance to cisplatin, a standard chemotherapy agent.
The work centers on the synthesis of coordination compounds, frequently using Schiff base ligands, followed by structural characterization and biological testing. Researchers investigate how these complexes interact with DNA and evaluate their anticancer activity against lung, breast, ovarian, and gastric cancers. A significant portion of the literature focuses on overcoming cisplatin resistance and mitigating cisplatin-induced kidney injury. Computational methods, such as molecular docking and density functional theory, are routinely used to model these interactions and predict biological activity before experimental validation.
The largest share of the community's output is found in platinum research, accounting for 14.6% of all platinum research, and 23,503 papers here. Ruthenium research represents 7.4% of that element's total output, with 5,776 papers in this group.
The community comprises 62,494 papers, published most frequently in Inorganica Chimica Acta, Journal of Inorganic Biochemistry, and Inorganic Chemistry.
Recent work continues to focus on the design of new ruthenium and iridium complexes for photoactivated therapies and the detailed study of copper complex mechanisms as anticancer agents.